Gene-edited babies, Takeda-Shire and more—FiercePharmaAsia by Angus Liu Friday, November 30, 2018 A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.
China's drug list, Rituxan biosim and more—FiercePharmaAsia by Angus Liu Friday, October 12, 2018 Cancer drugmakers cut prices by 56.7% for China; Celltrion's Rituxan biosim wins FDA panel support; Otsuka renews digital pill deal with Proteus.
Gene therapy cures might not deliver sustainable sales: analyst by Arlene Weintraub Thursday, April 12, 2018 This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?
Allergan enlists rapper Common to push eye screenings by Carly Helfand Tuesday, March 14, 2017 After launching a vision-loss awareness effort last month, Allergan has teamed up with its first celebrity spokesman: Common.
